Big pharma eyes Australian biotech as $300b patent cliff looms
Sep 6, 2026 – 2.05pmWhen Swiss pharmaceutical giant Novartis paid more than $2 billion for cancer therapy company Myricx last month, it was a wake-up call for Australian venture capital and superannuation funds which have had mixed luck with the …